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Abstract
Variation in body iron is associated with or causes diseases, including anaemia and iron overload. 
Here we analyse genetic association data on biochemical markers of iron status from eleven 
European-population studies, with replication in eight additional cohorts (total up to 48,972 
subjects). We find eleven genome-wide-significant (p < 5 × 10−8) loci, some including known 
iron-related genes (HFE, SLC40A1, TF, TFR2, TFRC, TMPRSS6) and others novel (ABO, 
ARNTL, FADS2, NAT2, TEX14). SNPs at ARNTL, TF, and TFR2 affect iron markers in HFE 
C282Y homozygotes at risk for hemochromatosis. There is substantial overlap between our iron 
loci and loci affecting erythrocyte and lipid phenotypes. These results will facilitate investigation 
of the roles of iron in disease.
INTRODUCTION
Absorption, transport and storage of iron are tightly regulated, as expected for an element 
which is both essential and potentially toxic. Iron deficiency is the leading cause of 
anaemia1, and it also compromises immune function2 and cognitive development 3. Iron 
overload damages the liver and other organs in hereditary hemochromatosis 4, and in 
thalassemia patients with both transfusion and non-transfusion-related iron accumulation5. 
Excess iron has harmful effects in chronic liver diseases caused by excessive alcohol, 
obesity or viruses6. There is evidence for involvement of iron in neurodegenerative 
diseases7, 8, 9, and in Type 2 diabetes10, 11. Variation in transferrin saturation, a biomarker of 
iron status, has been associated with mortality in patients with diabetes12 and in the general 
population13. All these associations between iron and either clinical disease or pathological 
processes make it important to understand the causes of variation in iron status. Importantly, 
information on genetic causes of variation can be used in Mendelian randomisation studies 
to test whether variation in iron status is a cause or consequence of disease14, 15.
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We have used biomarkers of iron status (serum iron, transferrin, transferrin saturation and 
ferritin), which are commonly used clinically and readily measurable in thousands of 
individuals, and carried out a meta-analysis of human genome-wide association study 
(GWAS) data from eleven discovery and eight replication cohorts. These phenotypes show 
significant heritability in normal adults16, 17, and previous population-based studies have 
identified relevant SNPs and gene loci (HFE, TF, TFR2 and TMPRSS618, 19) for iron status 
biomarkers. HFE and TMPRSS6 have also been shown to affect red cell count, hemoglobin 
and erythrocyte indices20, most likely by affecting iron availability20, 21, 22.
Our aims were to identify additional loci affecting markers of iron status in the general 
population and to relate the significant loci to information on gene expression in order to 
identify relevant genes. We also made an initial assessment of whether any such loci affect 
iron status in HFE C282Y homozygotes, who are at genetic risk of HFE-related iron 
overload (hereditary hemochromatosis type 1, OMIM #235200).
Combination of results from discovery and replication stages of our analysis shows 
significant effects on one or more of the iron biomarkers at 11 loci. Those primarily 
affecting serum iron and transferrin saturation include, or are close to, genes whose products 
have recognised roles in iron homeostasis; HFE (the haemochromatosis gene), TMPRSS6 
(transmembrane protease, serine 6) and TFR2 (transferrin receptor 2). Those mainly 
affecting serum transferrin, apart from the TF (transferrin) gene itself and TFRC (transferrin 
receptor), and those mainly affecting ferritin (apart from SLC40A1, solute carrier family 40 
(iron-regulated transporter), member 1) are unexpected. There is significant overlap between 
the genes or loci affecting iron biomarkers and those known to affect erythrocyte numbers or 
size, which is reasonable given the importance of iron for erythropoesis. We also find 
significant overlap between genes or loci affecting iron biomarkers and known loci affecting 
plasma lipids or lipoproteins, showing an unexplained link between these areas of 
metabolism.
RESULTS
SNP and gene associations
The combination of allelic association data from eleven discovery and eight replication 
cohorts (Supplementary Tables 1 – 3) showed eleven loci with significant effects on one or 
more of the iron-related phenotypes (Table 1, Fig. 1, Supplementary Fig. 1 – 2, 
Supplementary Table 4). Four of these (HFE, TF, TFR2, TMPRSS6) were previously 
known to affect iron biomarker variation in the general population18, 19. Genes at two newly 
significant loci, SLC40A1 which codes for the cellular iron exporter ferroportin and TFRC 
which codes for the iron importer transferrin receptor 1, are known to be important for 
cellular iron homeostasis 23. The other five loci (chromosome 8 at 18.3 Mbp, nearest gene 
NAT2; chromosome 9 at 136.2 Mbp, nearest gene ABO; chromosome 11 at 13.4 Mbp, 
nearest gene ARNTL; chromosome 11 at 61.6 Mbp, nearest gene FADS2; chromosome 17 
at 54.1 Mbp, nearest gene TEX14) were not previously known to affect any of these 
phenotypes. These affect either transferrin (NAT2, ARNTL, FADS2) or ferritin (ABO, 
TEX14).
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Conditional analysis on the discovery cohorts (Table 1, Supplementary Fig. 4) showed 
additional independent signals at the TF locus for transferrin and transferrin saturation and at 
TMPRSS6 for iron. Gene-based analysis in the discovery cohort (Supplementary Table 5) 
gave significant results (critical p-value for testing of 17,000 genes < 3 × 10−6) for ferritin in 
a region covering two genes (C15orf43 and SORD) on chromosome 15, where individual 
SNPs gave only suggestive associations. Allelic associations across this region are also 
shown in Supplementary Fig. 2. This locus did not show any SNPs with genome-wide 
significance in the combined discovery + replication data.
In the replication cohorts, the lead SNPs at the eleven significant loci explained 3.4%, 7.2%, 
6.7%, and 0.9% of the phenotypic variance for iron, transferrin, saturation and (log-
transformed) ferritin, respectively.
Secondary analyses
In view of the known association between ferritin concentration and inflammatory 
conditions, we repeated the discovery meta-analysis of ferritin including C-reactive protein 
(CRP, a marker of inflammation) as a covariate. This resulted in a decrease in effect sizes 
(expressed as standardized regression slopes or betas in an additive-allelic-effect model) for 
the lead SNPs at significant and suggestive loci, to an average of 73% (SD 15%) of the 
previous betas (Supplementary Fig. 5). The p-values became less significant, partly because 
of the decrease in effect size and partly because the number of subjects with CRP data was 
less than the number available for the initial analysis.
To check whether results were similar after excluding people with iron deficiency, we 
removed subjects with serum ferritin concentration below 30 μg/l and repeated the meta-
analyses for all four phenotypes. This decreased effect sizes for transferrin and transferrin 
saturation, but had negligible effects for SNPs which were significant or suggestive for 
ferritin or iron compared to those from the all-subjects analysis (Supplementary Table 6).
We also examined the association between serum transferrin concentration and FADS2 
variation. Because this gene is known to be associated with other phenotypes related to 
lipids and components of the metabolic syndrome, we included high-density lipoprotein 
cholesterol (HDL-C) as a covariate and repeated the association meta-analysis for transferrin 
and the most significant SNP at the FADS2 locus, rs174577. (HDL-C was chosen because it 
was available for a greater proportion of subjects than either triglycerides or glucose, which 
are also associated with FADS polymorphisms.) This conditional analysis resulted in a 35% 
reduction in the effect size for this SNP, from β = 0.068 ± 0.011 to 0.044 ± 0.009.
Effects at Significant Loci on Gene Expression and Regulation
We next checked for data which may help explain the biological role of the significant SNPs 
or identify the causal variants which they tag, using sources listed in the Methods. The 
synthesis of information from our results and external sources is exemplified in Fig. 2, 
which shows the alignment of data at the TFR2 locus. The region which includes genome-
wide-significant SNPs (after replication) for serum iron contains documented eQTLs for 
TFR2, and H3K27Ac histone modification sites (documented in data from ENCODE). In 
this case, there is striking alignment at the region around 100.2 Mbp at one end of the TFR2 
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gene, which includes the most significant SNPs at this locus, documented eQTLs for this 
gene, and the histone modification in K562 (erythroleukaemia) cells.
A similar approach was taken for the other significant loci, as summarized in Supplementary 
Table 7. SNPs identified through the GWAS had significant cis-effects on expression of 
SLC40A1, TFRC, ARNTL, and FADS1/FADS2. At the C15orf43-SORD locus on 
chromosome 15, rs16976620 (allelic association with ferritin p = 4.52 × 10−7) affected 
expression of SORD at p = 4.02 × 10−4. The chromosome 22 region near TMPRSS6 
contains eQTLs for hepatic expression of TMPRSS624. However the chromosome 3 locus 
near TF contains eQTLs for SRPRB but not for TF; and SNPs at the loci identified as TFR2, 
ABO and TEX14 are eQTLs for multiple other genes. The ENCODE regulatory data show 
potential regulatory sequences or histone marks in the regions where we found SNP 
associations on chromosome 2 near SLC40A1, chromosome 11 near the FADS genes, and at 
the chromosome 17 locus near TEX14.
Some lead SNPs from our significant loci also showed trans-effects on more distant genes 
(Supplementary Table 7). Most notably, the three non-synonymous coding SNPs in HFE 
and TMPRSS6 (rs1800562, rs1799945 and rs855791) had strong effects on expression of 
ALAS2 (aminolevulinate, delta-, synthase 2), which catalyses the initial step in heme 
synthesis in erythroid tissues.
Overlap with other phenotypes and disease associations
Because of previous data showing that iron-related loci overlap with loci affecting 
erythrocyte phenotypes, and because several of our significant loci have been reported to 
affect lipid phenotypes, we compared our results against published meta-analysis data on 
erythrocytes and lipids. Results are summarized in Supplementary Table 8. Among the 75 
significant loci for erythrocyte phenotypes25, we found associations with one or more of our 
iron phenotypes after Bonferroni correction for multiple testing at p < 6.7 × 10−4 (p < 0.05 
adjusted for testing of 75 SNPs) for ABO, HFE, TFR2, TFRC and TMPRSS6, and 
additionally for HBS1L (p = 9.78 × 10−7 for transferrin saturation) and PGS1 (p = 1.84 × 
10−4 for ferritin). For the 157 lipid loci reported by the Global Lipids Genetics 
Consortium26, two loci (HFE and HBS1L) gave p < 3.18 × 10−4 (p < 0.05 adjusted for 
testing of 157 loci) for iron and saturation, six (FADS1/2/3, GCKR, HFE, NAT2, SNX5 and 
TRIB1) for transferrin, and six (ABO, HFE, LOC84931, LRP1, PGS1 and TRIB1) for 
ferritin. Moreover, plots of observed versus expected p-value distributions for the iron 
phenotypes (Fig. 3) showed that even the erythrocyte and lipid loci not reaching statistical 
significance do affect iron biomarkers to a greater degree than can be explained by chance.
The SNP association results were also analysed using Ingenuity Pathway Analysis, selecting 
SNPs which showed associations at p < 0.01, < 0.001 and < 0.0001 for transferrin saturation, 
and similarly for ferritin. Results for these two phenotypes, chosen as markers of iron 
availability and iron stores, showed substantial overlap. The p < 0.01 threshold identified an 
excess of genes which have been reported to affect or be associated with lung cancer, 
cardiovascular disease and diabetes; and also with a range of developmental and nerve cell 
functions (Supplementary Fig. 6). Results for the p < 0.001 threshold were similar but 
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showed lesser statistical significance, as expected because of the smaller number of genes 
included.
Effects on iron status in HFE C282Y homozygotes
We tested whether the lead SNPs at loci which affect iron-related biomarkers in the general 
population also explain variation in iron status in C282Y homozygotes who are at genetic 
risk of HFE-related iron overload. These comprised 76 homozygotes from the QIMR Adult 
cohort (one of the discovery cohorts), plus 277 homozygotes from the HEIRS study27. 
Results are shown in Table 2 for significant associations, and more fully in Supplementary 
Table 10.
The strong association between rs8177240 in the TF gene and serum transferrin was clearly 
present in HFE YY homozygotes (p = 1.93 × 10−9). The YY group showed association 
between serum iron and rs7385804 at TFR2 (β = 0.178 ± 0.053, p = 0.00076, critical p-value 
= 0.005 after adjusting for testing of ten loci). The standardized beta for this SNP was 
approximately three times as great in the YY sample as in the overall meta-analysis (0.178 ± 
0.053 against 0.055 ± 0.010). There was also a significant association (p = 0.0022) between 
rs6486121 in ARNTL and ferritin. When we checked for associations between a genetic risk 
score calculated from the significant and suggestive SNPs in the population-based meta-
analysis results, and the biomarker phenotypes in the HEIRS sample, only transferrin 
showed a significant association and this was stronger among the men than the women 
(Supplementary Table 11).
DISCUSSION
Our meta-analysis of GWAS on iron-related phenotypes from up to 48,000 people of 
European descent showed multiple significant associations. Some increased the significance 
of loci known from previous studies or showed significant associations with additional 
phenotypes (TF, TFR2, HFE, TMPRSS6); some were at loci containing genes whose 
products have known roles in iron homeostasis, including the transferrin receptor TFRC and 
the iron transporter ferroportin (SLC40A1); and others were novel (near to ARNTL, FADS2 
and NAT2 for transferrin, ABO and TEX14 for ferritin). Significant associations were found 
for biomarkers of iron status that reflect both cellular iron metabolism and systemic 
regulation of iron23.
There was variation in the phenotypes affected by the significant loci, as summarized In 
Supplementary Fig. 3. Three of the loci mainly affected serum ferritin (ABO, SLC40A1, 
TEX14); three others mainly affected serum iron and transferrin saturation (HFE, TFR2, 
TMPRSS6); and five mainly affected serum transferrin (ARNTL, FADS2, NAT2, TF and 
TFRC). The loci with the strongest effects on serum iron (HFE, TMPRSS6) had significant, 
but smaller, effects on serum ferritin and it is likely that this is due to higher circulating 
concentrations of iron leading over time to higher iron stores and hence higher serum 
ferritin.
We note that there are factors which can modify the relationships between these biomarker 
phenotypes and whole-body or tissue-specific iron status. Ferritin has been criticised as a 
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marker of iron stores because it is an acute-phase protein increased by inflammation, but 
comparisons with independent methods28, 29 have validated it sufficiently for use in 
epidemiological studies. Moreover the loci which affected ferritin in this study have not 
been reported in GWAS for inflammatory biomarkers or CRP30, and SLC40A1, which 
showed a highly significant association with ferritin, has strong biological plausibility 
because it codes for ferroportin. Including CRP as a covariate in the ferritin association 
analysis changed the effect size similarly for all the significant or suggestive SNPs 
(Supplementary Figure 5), whereas effects related to both inflammation and iron status 
would be expected to alter betas for some SNPs and not others.
We also note that matching of significant loci to genes is subject to uncertainty. For some, 
the location of the peak association close to a gene with a known and relevant physiological 
function gives confidence in the gene assignment. For others, data from previous reports or 
databases on association between SNPs and gene expression will identify a probable gene, 
but in other cases expression data are consistent with any of several genes or else no relevant 
data are available. If so, the name of the nearest gene may be provided for identification of 
the locus but this may require revision as more information becomes available.
Five confirmed loci contain genes (TF, TFR2, HFE, TMPRSS6, SLC40A1) which were 
already known to affect iron homeostasis. These genes have been previously identified via 
monogenic diseases or from functional studies. Interestingly, no association has been 
identified with genes for several other important players in iron homeostasis such as ferritin, 
the protein that safely stores excess iron, or hepcidin and hemojuvelin, which are essential in 
the hepcidin signalling pathway and when mutated cause severe juvenile-onset 
hemochromatosis (type 2A, 2B). Mutations at the loci identified cause late-onset (HFE, type 
1) or less severe (TFR2, type 3 and SLC40A1, type 4A) hemochromatosis.
SNPs at HFE and TMPRSS6 which mainly affect iron and transferrin saturation showed 
interesting trans-effects on gene expression for ALAS2. As this gene is on the X 
chromosome and we only analysed GWAS data for autosomes, we do not know whether 
ALAS2 variation affects our phenotypes. However, ALAS2 activity controls the initial and 
rate-limiting step in porphyrin synthesis so a co-ordinated effect on both iron and 
protoporphyrin availability for formation of heme is an interesting possibility.
SLC40A1 is a prime candidate for affecting iron stores, as it codes for ferroportin and 
mutations in this gene are associated with the autosomal dominant type 4 hemochromatosis, 
characterized by high ferritin levels. The most significant SNPs near SLC40A1 in our study 
are about 45 and 60 kbp from the gene, but are known to affect SLC40A1 expression. 
Variation near SLC40A1 also affects transferrin, probably through an effect on cellular iron 
availability.
Genome-wide studies of erythrocyte traits known to vary with iron status20, 21, 22, 25 have 
previously found associations with many of these loci: erythrocyte volume (MCV) and 
hemoglobin content (MCH) with HFE, TFR2, TFRC and TMPRSS6; hematocrit with HFE, 
TFR2, and TMPRSS6; and erythrocyte count with TFR225. The results for our iron data at 
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loci known to affect erythrocyte phenotypes are illustrated in Fig. 3a; an unexpectedly high 
proportion of them affect iron, transferrin and ferritin.
New associations were found for ferritin near ABO and TEX14. The ABO blood group 
locus has shown significant associations for several phenotypes; rs651007 has a particularly 
strong effect on E-selectin31 and has also been found in GWAS on low-density lipoprotein 
cholesterol32, coronary artery disease33 and red blood cell count25. The latter is relevant to 
our ferritin finding, but whether ABO variation primarily affects iron stores and therefore 
erythrocyte count, or vice versa, is unclear.
TEX14 codes for a testis-expressed protein, but there was no evidence for male-female 
heterogeneity in the effect on ferritin (pHet for the lead SNP, rs368243, was 0.45). The most 
significant SNPs are within the TEX14 gene but the suggestive-significance region extends 
across other genes. Expression data suggest that variation affecting RAD51C may be 
important, but the function of this gene (in DNA repair and meiosis) also has no obvious 
connection with iron status. The same holds for SEPT4, for which rs411988 is an expression 
QTL. Another gene within the LD block, MTMR4, deserves consideration because it 
changes SMAD phosphorylation, with possible effects on the BMP-SMAD pathway 
affecting control of hepcidin34. The region on chromosome 15 identified in the gene-based 
analysis is centered on C15orf43 but also overlaps with SORD (sorbitol dehydrogenase). 
SORD has no obvious connection with iron status and the function of the protein coded by 
C15orf43 is unknown, although there is some evidence that it is present in human plasma 
(http://pax-db.org/#!protein/986968, accessed 2014-03-27). These two loci illustrate the 
difficulty which may be encountered in interpreting allelic associations; in some cases the 
region containing the most significant results overlaps with several genes, there may be 
unrecognised regulatory regions with effects on more distant genes, and data on gene 
expression may not reflect expression in the relevant tissue. For all these reasons, 
assignment of significant effects to specific genes must often be provisional.
Effects on transferrin were seen for most of the loci which affect serum iron, including HFE, 
TF, TFRC, and TMPRSS6. Contrary to the result for TFRC, variation at the other transferrin 
receptor gene TFR2 did not affect transferrin concentration; this may reflect the different 
functions of the two receptors. TfRC is involved in cellular iron uptake, which may directly 
affect regulation of transferrin expression. TfR2 on the other hand has been reported to be 
involved in hepatocyte sensing of circulating iron and signalling to hepcidin production, 
which may subsequently affect circulating levels of iron and the transferrin saturation. TfR2 
variation could also affect these iron parameters through its effect on erythropoiesis35.
Transferrin was also affected by SNPs near ARNTL, NAT2 and FADS2. The role of these 
in iron homeostasis is uncertain; transferrin is central to iron transport and receptor-mediated 
uptake by cells but these loci did not affect serum iron or ferritin. ARNTL, and its product 
BMAL1, is mainly known for interactions with CLOCK genes and generation of circadian 
rhythm. Notably, serum iron16, 36, liver iron37, hepcidin38, and TfR1 gene expression39 all 
show circadian variation. The region affecting transferrin on chromosome 8 contains the 
NAT2 gene, which again has no obvious relevance for iron. It has been shown to affect 
lipids32 and cardiovascular risk (see Supplementary Table 8 of 40). The gene product is 
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important for xenobiotic metabolism; NAT2 codes for an N-acetyl transferase which 
determines fast- or slow-acetylator status. At FADS2, the significant SNPs for transferrin 
are intronic but they affect expression of FADS genes. FADS1/2/3 variation affects a wide 
range of phenotypes including serum lipids32, 41, polyunsaturated fatty acid content of serum 
phospholipids42; fatty acid composition of membranes and phospholipids43; fasting glucose 
and insulin response44, 45, and liver enzymes46. The most significant FADS SNPs for lipids 
are rs174546, rs174547 and rs17454832, 41, 47 and each gave significant or near-significant 
p-values for transferrin in our data (p = 7.43 × 10−10, 8.47 × 10−10 and 7.29 × 10−8, 
respectively). This, together with the decrease in the locus effect on transferrin after 
inclusion of HDL-C as a covariate, suggests a common basis for effects on lipids and 
transferrin. The pathways involved are unknown, but iron homeostasis and lipid metabolism 
show overlap in the literature32, 48, 49, 50, 51 as well as in our data. It has recently been 
shown, for example, that signalling pathways for the protein kinase mTOR, which regulates 
energy metabolism and lipid synthesis among other functions52, affect transcriptional 
control of hepcidin and therefore potentially affect iron uptake and distribution53.
Despite the varied functions of these three genes (ARNTL, FADS2, NAT2) which 
unexpectedly affect transferrin, they have the common feature of significant effects on 
plasma triglycerides26. Detailed comparison of our results against published lipid loci 
showed that a high proportion of lipid loci (not only for triglycerides) have detectable effects 
on our iron phenotypes, especially on transferrin (Fig. 2b, Supplementary Table 8). The 
pleiotropic effects at such loci, connecting iron homeostasis not only with erythropoiesis but 
also with lipids and possibly with cardiovascular risk, deserve further investigation.
One important clinical question about iron overload is why some HFE C282Y homozygotes 
develop biochemical evidence of iron overload and clinical symptoms of hemochromatosis, 
while most do not54. A systematic review of longitudinal studies found that 38–76% of 
homozygous people have increased ferritin and transferrin saturation (biochemical 
penetrance)55. However, clinical symptoms are less common at 2–38% in men and 1–10% 
in women56, 57. We therefore evaluated the effects of our lead SNPs in HFE C282Y 
homozygotes, combining data from the largest of our Discovery cohorts with available 
phenotypic information and DNA from participants in the HEIRS study.
Because of limited numbers of C282Y homozygotes (total N available for data analysis was 
353), we had limited power to detect relevant effects. Among our results, the association 
between two SNPs in TFR2 and serum iron seems the most relevant. There is both clinical 
and experimental evidence for interaction between the gene products of HFE and TFR2. 
Severe juvenile hemochromatosis occurred in a family carrying mutations in both HFE and 
TFR258. In mice, homozygosity for deletion of both Hfe and TfR2 greatly decreases 
hepcidin levels59 and causes massive iron overload60. These reports are consistent with 
evidence that TFR2 and HFE proteins interact in control of hepcidin signaling; they may 
form an iron-sensing complex that modulates hepcidin expression in response to blood 
levels of diferric transferrin61, 62.
Overall, there was a lack of correlation between effect sizes for lead SNPs at the significant 
loci identified in the general population, and in the YY homozygotes. Similarly, a predictor 
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based on allele count and effect size for SNPs taken forward for replication and genotyped 
in the HEIRS subjects did not significantly predict iron, saturation or ferritin in the HEIRS 
C282Y homozygotes (Supplementary Table 11 and Supplementary Figure 7). The 
exception, transferrin, was due to the strong effects at the TF locus.
Previous studies have proposed determinants of HFE clinical or biochemical penetrance. 
Apart from age, sex and probably alcohol intake63, the focus has been on genetic modifiers 
but no candidate has been convincingly identified64. Since iron homeostasis involves a 
complex regulating network23, 65, it seems probable that any genetic effects on penetrance 
are either highly polygenic (in which case large genome-wide studies on HFE C282Y 
homozygotes will be needed) or result from rare variants which have not yet been examined 
in sufficient detail. TFR2 variation as a modifier of HFE C282Y risk has statistical support 
and biological plausibility but confirmation is needed.
Our results have revealed genes or loci whose effects on iron status were previously 
unsuspected and which need to be integrated into our understanding of iron homeostasis. 
Discovery of SNPs which significantly affect iron status, and compilation of genomic 
scores, will allow Mendelian randomisation studies on the multiple conditions associated 
with variation in iron load and help to clarify a potential causal role of iron in such 
conditions (e.g. Parkinson’s14 or Alzheimer’s 66 diseases). However the existence of 
pleiotropic effects, with many loci affecting both iron and lipid phenotypes, shows the need 
for caution in selecting SNPs or scores for such applications.
METHODS
Subjects
We established the Genetics of Iron Status Consortium (GISC) to coordinate our efforts in 
understanding the causes and consequences of genetic variation in biochemical markers for 
iron status, i.e. serum iron, transferrin, transferrin saturation and ferritin. Discovery samples 
consisted of summary data on genome-wide allelic associations between SNP genotypes and 
iron markers from 23,986 subjects of European ancestry gathered from 11 cohorts in 9 
participating centres (Supplementary Table 1). Replication samples to confirm suggestive 
and significant associations were obtained from up to 24,986 subjects of European ancestry 
in 8 additional cohorts (also in Supplementary Table 1). There was no systematic selection 
whether a cohort was allocated into the discovery or replication samples. This allocation was 
based on the availability of data when the analyses were conducted. Information on 
phenotypic means, methods for phenotype measurement, and genotyping methods for each 
contributing cohort are shown in Supplementary Tables 2 and 3. Each participating study 
was approved by the appropriate human research ethics committee, as listed for each study 
in Supplementary Table 1, and all subjects gave informed consent.
Genome-wide association studies
Genome-wide association tests, genotype imputation and associated quality control 
procedures (QCs) were performed in each cohort separately. Within each cohort, QCs were 
applied to individual samples and SNPs prior to imputation into HAPMAP II (Release 22, 
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NCBI Build36, dbSNP b126) or, for InterAct, 1000 Genomes. These include removing 
individuals based on missingness, relatedness, population and ethnic outliers. Poor-quality 
SNPs were also removed based on missingness, minor allele frequency, Hardy-Weinberg 
equilibrium test and Mendelian errors for family data. These QCs for each cohort are 
summarized in Supplementary Table 3.
The association between genotyped and imputed SNPs and each iron phenotype was 
performed using an additive model for allelic effects, on the standardized residuals of the 
phenotype after adjusting for age, principal component scores and other study specific 
covariates, for each sex separately. The details of the association analysis and imputation 
method for each cohort are presented in Supplementary Table 3.
Meta-analysis
We conducted meta-analysis of GWAS results from the discovery cohorts in the Metal 
package67 using a standard error based approach, which weights the SNP effect size 
(standardized regression slope, beta) using the inverse of the corresponding squared standard 
errors. SNPs were included in the meta-analysis if they met the following conditions: 
imputation quality score either Rsq (which estimates the squared correlation between 
imputed and true genotypes) for MACH software >=0.3, or the ‘info’ measure for IMPUTE 
software > 0.5; Hardy-Weinberg Equilibrium Test p-value (pHWE) >=10−6; minor allele 
frequency (MAF) >=0.01; genotyping Call Rate >=0.95 and if they survived QCs in all 
cohorts to avoid disproportionate contribution of a single cohort to the meta-analysis. In 
total ~2.1 million SNPs met these conditions. A genomic control correction was applied to 
all cohorts. Heterogeneity of effect sizes between cohorts or between sexes was also 
assessed using Cochran’s Q statistic within Metal. Loci containing SNPs with p < 5 × 10−6 
were carried forward for in silico replication in independent samples, again using Metal for 
the meta-analysis. The threshold p-value for choice of SNPs for replication is conventional 
and based in part on data for European populations in Duggal et al68.
Power to detect allelic effects was estimated using the Genetic Power Calculator (http://
pngu.mgh.harvard.edu/~purcell/gpc/). Under reasonable assumptions about allele 
frequencies for causative and marker polymorphisms (QTL increaser allele frequency = 0.2, 
marker allele frequency = 0.2, linkage disequilibrium between them d′ = 0.8, α = 5 × 10−8), 
the Discovery dataset with N = 24,000 gives 77% power to detect allelic effects which each 
account for 0.25% of the phenotypic variance.
Gene-based analysis
Gene-based analysis considers all SNPs within a gene as a unit for the association analysis. 
We performed gene-based analysis on SNP association p-values from the meta-analysis of 
discovery samples using VEGAS (http://gump.qimr.edu.au/VEGAS/, accessed 
2014-03-27)69. The significance of gene-based analysis was based on Bonferroni correction 
of testing ~17,000 genes (i.e. p < 3 × 10−6).
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Conditional analysis
To find independent signals within each significant locus, we performed conditional analysis 
in each cohort by repeating the association analysis but including the most significant SNP 
at each significant locus (in the initial meta-analysis) as covariates. We performed meta-
analysis of the conditional association results using the same approach as in the main meta-
analysis.
Gene expression
The eQTL look-up was based on a meta-analysis of expression data for known disease-
associated loci in non-transformed peripheral blood cells, from 5,300 samples from seven 
cohorts. The original analysis used HapMap2 imputed SNPs and a cis-window of +/− 250kb 
from the transcription start-site. More details can be found in the paper by Westra et al.70.
Information on gene expression in macrophages and monocytes was based on results 
obtained by the Cardiogenics consortium, on 758 samples, as described in the 
Supplementary Note to 33. Online resources for gene expression and regulation included 
http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/, http://genenetwork.nl/bloodeqtlbrowser/ and 
Schadt et al. (2008) 24 for eQTL data, http://genome.ucsc.edu/ENCODE/ for information on 
histone modification, and http://ecrbrowser.dcode.org/ for comparison of DNA sequences 
across species.
Bioinformatic analyses
Pathway analysis and assessment of known disease associations or biological functions was 
performed using Ingenuity Pathway Analysis (IPA; Ingenuity Inc, Redwood City, CA, 
94063), selecting SNPs which showed associations at p < 0.01, < 0.001 and < 0.0001 for 
transferrin saturation, and similarly for ferritin. IPA compares the list of genes associated 
with the selected SNPs against a proprietary library of gene-disease and gene-function 
associations and tests frequencies of observed and expected occurrences.
Analysis in HFE C282Y homozygotes
Data and DNA samples from HFE C282Y homozygotes in the HEIRS study27 were 
obtained from the NIH Biologic Specimen and Data Repository Information Coordinating 
Center (BioLINCC) (https://biolincc.nhlbi.nih.gov/home/)]. HEIRS was a population-based 
survey of the prevalence and effects of HFE polymorphisms, and subjects were not selected 
for having a diagnosis or positive family history of hemochromatosis. Selected SNPs (those 
showing significant or suggestive results in our primary meta-analysis) were genotyped by 
primer-extension mass spectrometry (MassArray, Sequenom Inc, San Diego CA); all 
samples were confirmed as being homozygous for the minor allele of rs1800562 by this 
method. Allelic association results for the QIMR adults and HEIRS C282Y homozygotes 
were combined by meta-analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plots for the associations between SNPs and iron status (serum iron, 
transferrin, transferrin saturation and ferritin)
The −log(p) values are from inverse-variance-weighted meta-analysis of the combined 
Discovery + Replication datasets for SNPs taken forward for replication, otherwise from the 
Discovery datasets only. Genes are assigned to the loci as follows: 1 SLC40A1; 2 TF; 3 
TFRC; 4 HFE; 5 TFR2; 6 NAT2; 7 ABO; 8 ARNTL; 9 FADS2; 10 TEX14; 11 TMPRSS6. 
Note that the y-axis for −log(p) values is truncated at 20.
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Figure 2. Comparison of results for serum iron with regulatory features at the chromosome 7 
(TFR2) locus
From bottom: regional association plot with recombination rate and −log(p) values for 
serum iron; documented eQTL locations for TFR2 expression (from left to right: 
rs10247962, rs4729598, rs7457868, rs4729600, rs1052897); ENCODE data on histone 
modification. P-values for serum iron at rs7385804 and rs2075672 are shown as text (Final 
p) for the Discovery + Replication dataset, but positions for all SNPs on the y-axis are 
determined by the Discovery dataset only.
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Figure 3. Q-Q plots of the association p-values for iron, transferrin and ferritin at loci previously 
reported to be significant for (a) erythrocyte phenotypes25 and (b) plasma lipid phenotypes26
For clarity, the y-axes only extend to p < 10−8 or p < 10−6 so that two associations with 
observed p < 10−8 for erythrocyte loci (at HFE and TMPRSS6) and four associations with p 
< 10−6 for lipid loci (at ABO, FADS2, HFE and NAT2) are not plotted. The interrupted line 
in each plot is the line of equivalence, observed = expected.
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